Off-label use of cardiovascular medications in children hospitalized with congenital and acquired heart disease

Circulation: Cardiovascular Quality and Outcomes

Volumn 1, Issue 2, 2008, Pages 74-83

  Pasquali, Sara K ^a   Hall, Matthew ^b   Slonim, Anthony D ^c   Jenkins, Kathy J ^d   Marino, Bradley S ^e   Cohen, Meryl S ^f   Shah, Samir S ^f  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Child Health Corporation of America   (United States)

^c CARILION CLINIC   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e UNIVERSITY OF CINCINNATI   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Congenital; Heart defects; Pediatrics; Pharmacology

Indexed keywords

ADRENALIN; ADRENERGIC RECEPTOR STIMULATING AGENT; CARDIOTONIC AGENT; DOPAMINE; FUROSEMIDE; LOOP DIURETIC AGENT;

ARTICLE; CHILD; CLINICAL PRACTICE; CONGENITAL HEART MALFORMATION; DRUG APPROVAL; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; INFANT; MALE; OFF LABEL DRUG USE; PRESCHOOL CHILD; STATISTICS; UNITED STATES;

ADRENERGIC AGONISTS; CARDIOTONIC AGENTS; CHILD; CHILD, PRESCHOOL; DOPAMINE; DRUG APPROVAL; EPINEPHRINE; FEMALE; FUROSEMIDE; GRAFT REJECTION; HEART DEFECTS, CONGENITAL; HEART TRANSPLANTATION; HUMANS; INFANT; MALE; OFF-LABEL USE; PHYSICIAN'S PRACTICE PATTERNS; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS; UNITED STATES;

EID: 77951196285     PISSN: 19417713     EISSN: 19417705     Source Type: Journal    
DOI: 10.1161/CIRCOUTCOMES.108.787176     Document Type: Article

References (20)

1. Lee PY, Alexander KP, Hammill BG, Pasquali SK, Peterson ED. Representation of elderly persons and women in published randomized trials of acute coronary syndromes. JAMA. 2001;286:708-713. (Pubitemid 33010364)
2. Shah SS, Hall M, Goodman D, Feuer P, Sharma V, Fargason C Jr, Hyman D, Jenkins K, White ML, Levy FH, Levin JE, Bertoch D, Slonim AD. Off-label drug use in hospitalized children. Arch Pediatr Adolesc Med. 2007;161:282-290. (Pubitemid 46364332)
3. The Pediatric Exclusivity Provision, January 2001 Status Report to Congress. Available at www.fda.gov/cder/pediatric. Accessed February 1, 2008.
4. Best Pharmaceuticals for Children Act. Available at www.fda.gov/cder/ pediatric. Accessed February 1, 2008.
5. Mahony L, Sleeper LA, Anderson PA, Gersony WM, McCrindle BW, Minich LL, Newburger JW, Saul JP, Vetter VL, Pearson GD; Pediatric Heart Network Investigators. The Pediatric Heart Network: a primer for the conduct of multicenter studies in children with congenital and acquired heart disease. Pediatr Cardiol. 2006;27:191-198.
6. Pediatric Exclusivity Labeling Changes. Available at www.fda.gov/cder/ pediatric. Accessed February 1, 2008.
7. Sanders SP. Conducting pediatric cardiovascular trials. Am Heart J. 2001;142:218-223.
8. Duboc D, Meune C, Lerebours G, Devaux J, Vaksmann G, Becane H. Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. J Am Coll Cardiol. 2005;45:855-857. (Pubitemid 40342808)
9. Li J, Zhang G, Holtby H, Humpl T, Caldarone CA, Van Arsdell GS, Redington AN. Adverse effects of dopamine on systemic hemodynamic status and oxygen transport in neonates after the Norwood Procedure. J Am Coll Cardiol. 2006;48:1859-1864. (Pubitemid 44648610)
10. Shaddy RE, Boucek MM, Hsu DT, Boucek RJ, Canter CE, Mahony L, Ross RD, Pahl E, Blume ED, Dodd DA, Rosenthal DN, Burr J, La Salle B, Holubkov R, Lukas MA, Tani LY; Pediatric Carvedilol Study Group. Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA. 2007;12:1171-1179. (Pubitemid 47403103)
11. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334:1349-1355. (Pubitemid 26152713)
12. Li JS, Yow E, Berezny KY, Bokesch PM, Takahashi M, Graham TP Jr, Sanders SP, Sidi D, Bonnet D, Ewert P, Jennings LK, Michelson AD; PICOLO Investigators. Dosing of clopidogrel for platelet inhibition in infants and young children: primary results of the Platelet Inhibition in Children On Clopidogrel (PICOLO) trial. Circulation. 2008;117:553-559.
13. Children's Oncology Group Protocol List. Available at www.childrensoncologygroup.org. Accessed July 15, 2007.
14. 't Jong GW, Van Der Linden PD, Bakker EM, Van Der Lely N, Eland IA, Stricker BH, Van Den Anker JN. Unlicensed and off-label drug use in a paediatric ward of a general hospital in the Netherlands. Eur J Clin Pharmacol. 2002;58:293-297. (Pubitemid 34827859)
15. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology: drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349:1157-1167. (Pubitemid 37122329)
16. Yaster M, Nichols DG, Deshpande JK, Wetzel RC. Midazolam-fentanyl intravenous sedation in children: case report of respiratory arrest. Pediatrics. 1990;86:463-467. (Pubitemid 20334983)
17. Bajcetic M, Jelisavcic M, Mitrovic J, Divac N, Simeunovic S, Samardzic R, Gorodischer R. Off label and unlicensed drug use in paedeatric cardiology. Eur J Clin Pharmacol. 2005;61:775-779. (Pubitemid 41674265)
18. List of Drugs for Which Pediatric Studies Are Needed: Federal Register notice 71FR23931 (issued 4/25/2006). Available at www.fda.gov/cder/pediatric. Accessed July 15, 2007.
19. Pediatric Heart Network, current studies. Available at www.pediatricheartnetwork.org.; Accessed July 15, 2007.
20. Hoffman TM, Wernovsky G, Atz AM, Kulik TJ, Nelson DP, Chang AC, Bailey JM, Akbary A, Kocsis JF, Kaczmarek R, Spray TL, Wessel DL. Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease. Circulation. 2003;107:996-1002. (Pubitemid 36258723)